Elcitonin
Evidence Grade C — Moderate human evidence. 150 published studies, 71 human. 1 registered clinical trial.
Elcatonin is a synthetic calcitonin analogue based on eel calcitonin, used in Japan and some Asian markets for osteoporosis-related pain management. Like salmon calcitonin, it slows bone breakdown, but its primary use in practice is for the pain of spinal fractures rather than fracture prevention.
150 published studies: 71 human, 54 animal, 16 in-vitro, 8 reviews
Elcatonin is marketed as Elcitonin (Asahi Kasei) in Japan and some Asian markets. It has been available since 1981 in those regions. It is not approved by the FDA or EMA.
Studies conducted in Japan indicate elcatonin is inferior to bisphosphonates for increasing bone density but may have specific utility for pain associated with vertebral fractures. Its regulatory status is limited to certain Asian jurisdictions, and its clinical evidence base does not meet FDA/EMA approval standards.
Elcatonin acts on the same calcitonin receptor as salmon calcitonin, inhibiting osteoclast activity and reducing bone breakdown. Research suggests it may also produce analgesic effects on bone pain through central nervous system pathways. The ethylene bridge modification provides greater chemical stability than the natural disulfide bond found in other calcitonin preparations.
Research suggests Japanese studies indicate elcatonin is less effective than bisphosphonates for increasing bone density but may have specific utility for pain associated with vertebral fractures. The 2012 cancer signal identified for salmon calcitonin by European regulators raises questions about whether elcatonin carries similar risks, though this has not been specifically evaluated. The evidence base is limited to regional studies without the large international fracture prevention trials that would be required for FDA or EMA approval. No head-to-head comparisons with modern osteoporosis treatments (denosumab, romosozumab) exist.
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
